

Together, we're advancing the prevention, detection, and treatment of Alzheimer's disease.

AD-RIDDLE addresses challenges in the management of Alzheimer's disease, speeding up patient access to healthcare providers and precision medicine.

As the global population ages, the number of people with dementia is forecasted to grow from over 57 million today to 153 million by 2050. While there's great potential for risk reduction and early interventions to improve patient outcomes, broadly available testing, diagnosis, and treatment options are essential to ensure our healthcare systems are prepared.

AD-RIDDLE is building a modular toolbox platform that will enable healthcare systems to mix, match, and tailor components to suit their unique needs and settings. It will support all stages of the clinical pathway, accelerating patient access to healthcare providers and precision medicine.

1

Digital Engagement Portal

AD-RIDDLE's digital portal will include self-guided assessment tools and pathways for timely referral to healthcare providers, and tailored resources that connect to the next step.

2

Accessible & Validated Screening Tools

Providers will have access to a suite of validated digital cognitive assessments and blood-based biomarkers, intended to increase accuracy in risk detection and early diagnosis.

3

Decision Support Toolkit

Uniting best-in-class research and clinical outcomes data to enable differential diagnosis and inform personalised plans for prevention, treatment and care.

4

Personalised Patient Therapies

Patients will be matched with the right interventions at the right time, including lifestyle interventions and pharmacological treatments.

We're collaborating to advance Alzheimer's research and care.

The AD-RIDDLE consortium unites 24 public and private leaders from across Europe to revolutionise the prevention and treatment of Alzheimer's disease.



The AD-RIDDLE toolbox platform builds on existing technology, tools, and biomarkers, many developed by project partners through earlier EU-funded projects, including WW-FINGERS.



A three-year real-world testing study will be conducted in healthcare settings across 6 European countries. Data from the AD-RIDDLE study will be hosted in a GDPR-compliant manner by EPND.

AD-RIDDLE's modular toolbox platform will match patients with the right interventions at the right time, at every stage of the clinical pathway.

